Bivatuzumab mertansine

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Bivatuzumab mertansine ^?

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD44 v6
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
ATC code	None
Chemical data
Formula	?
N (what is this?) (verify)

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.^[1]

[edit] References

^ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical cancer research : an official journal of the American Association for Cancer Research 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Belimumab Cixutumumab Conatumumab Daratumumab Drozitumab Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Pritumumab Radretumab Rilotumumab Robatumumab Teprotumumab Votumumab Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor): Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Ensituximab Girentuximab Indatuximab ravtansine Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Afutuzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Inotuzumab ozogamicin Labetuzumab Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Onartuzumab Oportuzumab monatox Pertuzumab Sibrotuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab